

Liqrev[®]

(Sildenafil) Oral Suspension

10 mg/mL

Why Liqrev?

Liqrev[®] is an FDA-approved ready-made liquid oral suspension of sildenafil for adult patients with issues swallowing. Liqrev is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening.

- ✓ **FDA-approved and ready-made for immediate use: just shake and dispense**
- ✓ **Eliminates lengthy and complex preparation of powder formulations**
- ✓ **Removes risks associated with unapproved compounded formulations**

	Liqrev[®] (Sildenafil) Oral Suspension	Crushed & Compounded Tadalafil/Sildenafil Tablets	Sildenafil Powder
FDA-approved oral liquid formulation:	Yes	No	Only after powder has been properly reconstituted by a pharmacist.
Ready made minimal preparation:	Yes. Shake & dispense	No	No. Time consuming 10-step process that must be performed by a pharmacist.
Liquid formulation is FDA tested to ensure potency, efficacy & safety:	Yes	No	Only after powder has been properly reconstituted by a pharmacist.
Shelf life of liquid formulation:	24 months	Unknown	60 days

ORDER LIQREV TODAY!

Product Information: 122mL bottle • NDC: 46287-055-01

Dosing & Administration

Liqrev is an oral suspension: 10 mg/mL.

Recommended Dosage in Adults - The recommended dosage of LIQREV is 20 mg orally three times a day. Shake well for at least 10 seconds before use.

Pediatric use information is approved for Viartis Specialty LLC's, REVATIO (sildenafil) tablets. However, because of Viartis Specialty LLC's marketing exclusivity rights, this drug product is not labeled with that information.

Liqrev is bioequivalent to Revatio (sildenafil) tablets.²

Important Safety Information

Contraindications


Liqrev is contraindicated in patients with concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension. Concomitant use of riociguat, a guanylate cyclase stimulator, Known hypersensitivity to sildenafil or any component of the oral suspension.



Consider this before Crushing/ Compounding

Crushed/compounded formulations of tablets are **NOT** FDA-approved and are **NOT** tested for safety and efficacy in their manipulated form.

ARE YOU GIVING THE RIGHT DOSE?



In addition to potency issues, other formulation concerns include:

- **Costly Protocols** - Crushing can require expensive safety protocols that take up valuable staff time
- **Short Shelf Life** - Crushed and compounded products can have variable and very costly, short shelf lives
- **Lengthy Powder Preparations** - Requires an extensive reconstitution process that must be performed by a pharmacist

Prescribe Liqrev A Safe & Effective Alternative

- Liqrev is available through select specialty pharmacies.
- Visit liqrev.com/specialty to download the prescription request form.
- Co-pay assistance is available for eligible patients.*

* Terms, limitations, and restrictions apply. Visit liqrev.com/prescribing for more information

Important Safety Information

Indications and Usage

Adults

LIQREV is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.

Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil) tablets. However, because of Viatris Specialty LLC's marketing exclusivity rights, this drug product is not labeled with that information.

Contraindications

LIQREV is contraindicated in patients with:

- Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension.
- Concomitant use of riociguat, a guanylate cyclase stimulator. PDE-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.
- Known hypersensitivity to sildenafil or any component of the oral suspension. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil.

Warnings and Precautions

- Vasodilation effects may be more common in patients with hypotension or on antihypertensive therapy.
- Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended.
- Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs.
- Pulmonary hypertension (PH) secondary to sickle cell disease: LIQREV may cause serious vaso-occlusive crises.

Adverse Reactions

Adults: Headache, dyspepsia, flushing, pain in limb, myalgia, back pain, and diarrhea

LIQ-00024

To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

- **Nitrates** - Concomitant use of LIQREV with nitrates in any form is contraindicated
- **Strong CYP3A Inhibitors** - Concomitant use of LIQREV with strong CYP3A inhibitors is not recommended.
- **Moderate-to-Strong CYP3A Inducers** - Concomitant use of LIQREV with moderate-to-strong CYP3A inducers (such as bosentan) decreases the sildenafil exposure.
- **Concomitant PDE-5 inhibitors** - Avoid use with VIAGRA or other PDE-5 inhibitors.

Dosage and Administration

Recommended Dosage in Adults - The recommended dosage of LIQREV is 20 mg orally three times a day. A calibrated measuring device is recommended to measure and deliver the prescribed dose accurately. Shake well for at least 10 seconds before use.

Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil) tablets. However, because of Viatris Specialty LLC's marketing exclusivity rights, this drug product is not labeled with that information.

To view full prescribing information please visit liqrev.com/prescribing-information.

